MAPT and Alzheimer disease: However, it is important to take into account that most data on the functional role of IL-23 in AD have been generated from mouse models, and in particular from the APP/PS1 model, which develops Aβ plaques by 6-8 months, but no tau pathology and does not cover all aspects of AD pathology (74).